[Corrigendum] Screening of hub genes and evaluation of the growth regulatory role of CD44 in metastatic prostate cancer

Lin,Junhao; Chen,Zhi; Li,Zuan; Nong,Deyong; Li,Ximing; Huang,Guihai; Hao,Nan; Liang,Jianbo; Li,Wei

doi:10.3892/or.2022.8343

July-2022 Volume 48 Issue 1

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

July-2022 Volume 48 Issue 1

Full Size Image

Correction Open Access

[Corrigendum] Screening of hub genes and evaluation of the growth regulatory role of CD44 in metastatic prostate cancer

Authors:
- Junhao Lin
- Zhi Chen
- Zuan Li
- Deyong Nong
- Ximing Li
- Guihai Huang
- Nan Hao
- Jianbo Liang
- Wei Li
View Affiliations / Copyright

Affiliations: Department of Urology, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi Zhuang Autonomous Region 530021, P.R. China

Copyright: © Lin et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
Article Number: 132
|
Published online on: June 6, 2022

https://doi.org/10.3892/or.2022.8343
Expand metrics +

Article

Oncol Rep 46: [Related article:] 196, 2021; DOI: 10.3892/or.2021.8147

Subsequently to the publication of the above article, the authors have realized that they inadvertently included images of the same mice in Figs. 7A [the Negative Control (NC) experiment] and 8A [the 5B-3CT + Docetaxel (10 mg/kg) experiment].

After having consulted their original data, the authors have realized that these mice were correctly shown in the paper for the experiments portrayed in Fig. 7A; therefore, the corrected version of Fig. 8 is shown on the next page, showing the mice pertaining to the 5B-3CT + Docetaxel (10 mg/kg) experiment in Fig. 8A. The authors are grateful to the Editor of Oncology Reports for allowing them the opportunity to publish a Corrigendum, and all the authors agree to this Corrigendum. Furthermore, they apologize to the readership for any inconvenience caused.

Figure 8.

Inhibition of CD44 suppresses tumorigenicity of prostate cancer cells in vivo and the CD44 inhibitor (SB-3CT) combined with docetaxel inhibits tumorigenicity of prostate cancer. (A) Tumors dissected from BALB/c nude mice are presented (n=5 for each group). (B) Tumor volume curve of NC, SB-3CT, SB-3CT + Docetaxel (5 mg/kg) and SB-3CT + Docetaxel (10 mg/kg) treatment groups. (C) Tumor weight of NC, SB-3CT, SB-3CT + Docetaxel (5 mg/kg) and SB-3CT + Docetaxel (10 mg/kg) treatment groups. (D and E) PDK1 and PFKFB4 expression levels were downregulated in the PC-3 + SB-3T group, PC-3 + SB-3T + Docetaxel (5 mg/kg) group and PC-3 + SB-3T + Docetaxel (10 mg/kg) group compared with the PC-3 + NC group. (F) PDK1 expression levels were downregulated in the PC-3 + SB-3T group, PC-3 + SB-3T + Docetaxel (5 mg/kg) group and PC-3 + SB-3T + Docetaxel (10 mg/kg) group compared with the PC-3 + NC group. (G) PFKFB4 expression levels were downregulated in the PC-3 + SB-3T group, PC-3 + SB-3T + Docetaxel (5 mg/kg) group and PC-3 + SB-3T + Docetaxel (10 mg/kg) group compared with the PC-3 + NC group. Data are analysed using an ANOVA with Tukey's post hoc test. Data are presented as the mean ± SD. *P<0.05. NC, negative control; PDK1, pyruvate dehydrogenase kinase 1; PFKB4, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4.

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

[Corrigendum] Screening of hub genes and evaluation of the growth regulatory role of CD44 in metastatic prostate cancer

This article is mentioned in:

Article

Figure 8.

Related Articles